You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

UACR

Showing 1 - 25 of 296
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Called SMART-Finder to Look for People With Increased Amounts of

Not yet recruiting
  • Type 2 Diabetes Mellitus
  • Chronic Kidney Disease
  • Finerenone (Kerendia, BAY94-8862)
  • Type 2 DM drugs
  • Multiple Locations, Germany
    Many locations
Jan 13, 2023

T2DM (Type 2 Diabetes), Metformin, SGLT2-Inhibitors Trial in Matsumoto (Tofogliflozin, Metformin)

Recruiting
  • T2DM (Type 2 Diabetes Mellitus)
  • +2 more
  • Matsumoto, Nagano, Japan
    Shinshu University
Jul 21, 2022

Evaluation of the Analytical Performance of ALLEGRO™ Instrument

Completed
  • Diabetes Mellitus
  • +2 more
  • HbA1c, Lipids, UACR
  • Jupiter, Florida
  • +2 more
Dec 15, 2021

Kidney Injury Severity and COVID-19

Completed
  • COVID-19
  • Kidney Injury
  • mRNA in urine test
  • Moscow, Russian Federation
    Sechenov University.
Feb 8, 2021

Chronic Kidney Diseases, Type2Diabetes Trial in Boston (Alert-based computerized decision support)

Recruiting
  • Chronic Kidney Diseases
  • Type2Diabetes
  • Alert-based computerized decision support
  • Boston, Massachusetts
    Brigham and Women's Hospital
Jan 11, 2023

Type 2 Diabetes Trial in Korea, Republic of (metformin, ipragliflozin, glimepiride)

Terminated
  • Type 2 Diabetes Mellitus
  • Busan, Korea, Republic of
  • +7 more
Apr 12, 2020

Type2diabetes, Diabetic Kidney Disease Trial (Investigational Product - MIB 626, Placebo)

Not yet recruiting
  • Type2diabetes
  • Diabetic Kidney Disease
  • Investigational Product - MIB 626
  • Placebo
  • (no location specified)
Mar 6, 2023

Diabetes, Microalbuminuria Trial in Seoul (semi-quantitative urine albumin-to-creatinine ratio test, standard quantitative spot

Completed
  • Diabetes
  • Microalbuminuria
  • semi-quantitative urine albumin-to-creatinine ratio test
  • standard quantitative spot urine albumin-to-creatinine ratio
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Mar 24, 2020

Diabetic Kidney Disease Trial in United States (TMX-049, Placebo)

Completed
Has Results
  • Diabetic Kidney Disease
  • Flagstaff, Arizona
  • +54 more
Jul 28, 2022

Chronic Kidney Disease Trial in Worldwide (Zibotentan, Dapagliflozin, Placebo)

Recruiting
  • Chronic Kidney Disease
  • Huntsville, Alabama
  • +251 more
Dec 22, 2022

Renal Insufficiency, Chronic, Cardiovascular Diseases, Diagnosis Trial in Guangzhou

Recruiting
  • Renal Insufficiency, Chronic
  • +2 more
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Nov 20, 2023

    Diabetic Nephropathies Trial in Tanta (Niclosamide, Placebo oral tablet)

    Completed
    • Diabetic Nephropathies
    • Tanta, Egypt
      Faculty of Pharmacy, Tanta University
    Oct 19, 2022

    Chronic Kidney Diseases Trial in Houston (1. Welcome package, 2. Welcome information (phone or text), 3. Produce delivery +

    Not yet recruiting
    • Chronic Kidney Diseases
    • 1. Welcome package
    • +4 more
    • Houston, Texas
    • +2 more
    Jul 31, 2023

    CKD to Inspect CKD Prevalence, Diagnosis Rates, Diagnostic

    Not yet recruiting
    • Chronic Kidney Diseases
      • (no location specified)
      Jul 18, 2023

      Type2diabetes, PreDiabetes, Renal Failure Trial in Duesseldorf, Heidelberg (Dapagliflozin (Forxiga®), Placebo matching

      Not yet recruiting
      • Type2diabetes
      • +2 more
      • Dapagliflozin (Forxiga®)
      • +2 more
      • Duesseldorf, Germany
      • +1 more
      Sep 18, 2023

      Heart Failure, Chronic Kidney Disease Trial in Worldwide (AZD9977, Dapagliflozin)

      Recruiting
      • Heart Failure
      • Chronic Kidney Disease
      • Hot Springs National Park, Arkansas
      • +279 more
      Feb 1, 2023

      Diabetic Kidney Disease Trial in Herlev (ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide,

      Recruiting
      • Diabetic Kidney Disease
      • ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
      • Herlev, Denmark
        Department of Nephrology, Herlev and Gentofte Hospital
      May 31, 2023

      Learn More How Chronic Kidney Disease Gradually Changes Over

      Active, not recruiting
      • Chronic Kidney Disease
      • No Intervention
      • Wuppertal, Germany
        Bayer
      Jun 21, 2023

      Chronic Kidney Disease Trial in Worldwide (Verinurad, Allopurinol, Placebo for Verinurad)

      Completed
      • Chronic Kidney Disease
      • Huntsville, Alabama
      • +165 more
      Jan 19, 2022

      Diabetic Nephropathies Trial in Worldwide (Placebo, BI 685509)

      Completed
      • Diabetic Nephropathies
      • Placebo
      • BI 685509
      • Victorville, California
      • +77 more
      Jan 26, 2023

      Diabetic Kidney Disease Trial in China (Qishen Yiqi Dripping Pills 3 bags, Low dose Qishen Yiqi Dripping Pills 3 bags, High

      Not yet recruiting
      • Diabetic Kidney Disease
      • Qishen Yiqi Dripping Pills placebo 3 bags
      • +2 more
      • Beijing, Beijing, China
      • +15 more
      Aug 22, 2023

      Urinary Exosome in Type 2 Diabetic Nephropathy and Evaluation of

      Active, not recruiting
      • Diabetic Nephropathy
      • Grouping based on previous laboratory results, no intervention.
      • Jinan, Shandong, China
        Qianfoshan Hospital
      Oct 24, 2023

      Urinary Exosome in Type 2 Diabetic Kidney Disease and Evaluation

      Active, not recruiting
      • Diabetic Nephropathy
      • Grouping based on previous laboratory results, no intervention.
      • Jinan, Shandong, China
        Qianfoshan Hospital
      Nov 8, 2023

      Diabetic Nephropathy Type 2 Trial (Empagliflozin 25 MG, Enalapril Maleate 20 mg)

      Not yet recruiting
      • Diabetic Nephropathy Type 2
      • Empagliflozin 25 MG
      • Enalapril Maleate 20 mg
      • (no location specified)
      May 9, 2022

      Diabetic Kidney Disease, IgA Nephropathy Trial (Placebo of SC0062, SC0062 low dose, SC0062 medium dose)

      Not yet recruiting
      • Diabetic Kidney Disease
      • IgA Nephropathy
      • Placebo of SC0062
      • +3 more
      • (no location specified)
      Jan 9, 2023